Like the molecular structure of your DNA, each breast tumor has characteristics and behaviors that are unique to each patient. We use the Mammaprint® and Blueprint® genomic lab tests to decode those traits so we can craft a targeted treatment plan specific to each patient’s individual needs.
Backed by peer-reviewed outcome data, the Mammaprint® 70-Gene Breast Cancer Recurrence Assay may be used to determine the risk that a patient’s cancer will return. A High Risk score means the cancer has a 3 in 10 chance of returning. A Low Risk result puts the chances at 1 in 10. Neither result is a guarantee that the malignancy will or will not come back, but the assessment helps us to make important decisions in designing an appropriate therapeutic approach.
The Blueprint® 80-Gene Molecular Subtyping Assay, meanwhile, peers below the surface to determine which of the tumor’s mutations are dictating the cancer’s behavior. When used with the Mammaprint assay, Blueprint may narrowly define each tumor into a subtype classification, affording us a clearer picture for a more precise treatment strategy.
Learn more about breast cancer diagnostics